D2B3
Pre-clinical biotechnology company developing a platform to transiently and specifically relax the blood–brain barrier to enable therapeutic delivery to the brain and central nervous system. The platform is described as compatible with multiple drug classes and intended to support development of CNS-targeted therapies.
Industries
Nr. of Employees
small (1-50)
Products
Proprietary blood–brain barrier modulation platform
A platform technology that transiently and specifically relaxes the blood–brain barrier to facilitate therapeutic targeting of the brain and central nervous system.
Proprietary blood–brain barrier modulation platform
A platform technology that transiently and specifically relaxes the blood–brain barrier to facilitate therapeutic targeting of the brain and central nervous system.
Services
Technical collaboration to apply the delivery platform to external drug candidates, including compatibility assessment and development support for CNS delivery.
Technical collaboration to apply the delivery platform to external drug candidates, including compatibility assessment and development support for CNS delivery.
Expertise Areas
- CNS-targeted drug delivery
- Blood–brain barrier modulation
- Preclinical development for neurologic indications
- Platform integration for multiple therapeutic modalities
Key Technologies
- Blood–brain barrier modulation
- CNS-targeted drug delivery platforms
- Preclinical in vivo models and assays
- Platform integration for therapeutic payloads
News & Updates
Awarded an Innovation Prize by an accelerator program (2024).
Recipient of the Best in Showcase - Biotech award at the 2024 Yale Innovation Summit.
Selected to participate in the MassBioDrive fall 2024 accelerator cohort.
Selected for the 2025 MBC Platinum Ticket award, including pre-seed funding and access to laboratory and discovery services.
Founder & CEO recognized as a winner of the CEO of the Year Awards Northeast USA 2025.
Awarded an Innovation Prize by an accelerator program (2024).
Recipient of the Best in Showcase - Biotech award at the 2024 Yale Innovation Summit.
Selected to participate in the MassBioDrive fall 2024 accelerator cohort.
Selected for the 2025 MBC Platinum Ticket award, including pre-seed funding and access to laboratory and discovery services.
Founder & CEO recognized as a winner of the CEO of the Year Awards Northeast USA 2025.